拓新药业
(301089)
| 流通市值：18.90亿 | | | 总市值：26.68亿 |
| 流通股本：8964.93万 | | | 总股本：1.27亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 322,788,021.11 | 211,303,670.02 | 92,502,151.55 | 378,343,569.65 |
| 营业总成本 | 366,546,973.55 | 239,261,294.13 | 103,589,969.11 | 434,776,823.75 |
| 其他经营收益 | | | | |
| 营业利润 | -43,397,606.67 | -28,672,984.67 | -13,427,430.39 | -71,757,465.59 |
| 利润总额 | -43,402,122.41 | -28,679,250.82 | -13,459,683.86 | -72,385,422.81 |
| 净利润 | -40,955,759.56 | -27,960,796.93 | -10,509,661.07 | -69,661,027.7 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | 1,317,652.71 |
| 综合收益总额 | -40,955,759.56 | -27,960,796.93 | -10,509,661.07 | -68,343,374.99 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 544,437,094.92 | 555,802,078.76 | 580,407,667.4 | 584,951,074.95 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,071,015,928.79 | 1,076,510,229.93 | 1,070,562,767.37 | 1,080,345,330 |
| 资产总计 | 1,615,453,023.71 | 1,632,312,308.69 | 1,650,970,434.77 | 1,665,296,404.95 |
| 流动负债: | | | | |
| 流动负债合计 | 138,664,496.35 | 140,106,175.42 | 141,319,977.43 | 145,969,427.37 |
| 非流动负债: | | | | |
| 非流动负债合计 | 31,741,543.08 | 33,882,026.38 | 34,752,270.43 | 35,150,292.13 |
| 负债合计 | 170,406,039.43 | 173,988,201.8 | 176,072,247.86 | 181,119,719.5 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,445,046,984.28 | 1,458,324,106.89 | 1,474,898,186.91 | 1,484,176,685.45 |
| 股东权益合计 | 1,445,046,984.28 | 1,458,324,106.89 | 1,474,898,186.91 | 1,484,176,685.45 |
| 负债和股东权益合计 | 1,615,453,023.71 | 1,632,312,308.69 | 1,650,970,434.77 | 1,665,296,404.95 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 256,546,159.76 | 172,154,543.87 | 83,680,191.25 | 310,238,086.68 |
| 经营活动现金流出小计 | 262,564,151.96 | 176,706,067.38 | 85,089,695.47 | 336,424,987.71 |
| 经营活动产生的现金流量净额 | -6,017,992.2 | -4,551,523.51 | -1,409,504.22 | -26,186,901.03 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 421,772,030.47 | 211,095,074.03 | 75,347,366.39 | 984,995,548.24 |
| 投资活动现金流出小计 | 445,527,609.6 | 243,591,084.32 | 66,877,871.02 | 914,454,904.42 |
| 投资活动产生的现金流量净额 | -23,755,579.13 | -32,496,010.29 | 8,469,495.37 | 70,540,643.82 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 91,835.73 | 91,835.73 | 51,785.4 | 14,167.01 |
| 筹资活动现金流出小计 | 1,224,188.16 | - | - | 1,224,188.16 |
| 筹资活动产生的现金流量净额 | -1,132,352.43 | 91,835.73 | 51,785.4 | -1,210,021.15 |
| 汇率变动对现金及现金等价物的影响 | -866,682.65 | -521,201.1 | -290,232 | -287,930.55 |
| 现金及现金等价物净增加额 | -31,772,606.41 | -37,476,899.17 | 6,821,544.55 | 42,855,791.09 |
| 期末现金及现金等价物余额 | 72,864,917.93 | 67,160,625.17 | 111,459,068.89 | 104,637,524.34 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -37,476,899.17 | - | 42,855,791.09 |